EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
7.33 (USD) • At close December 24, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 46.018 | 41.404 | 36.939 | 34.437 | 20.365 | 2.961 | 7.539 | 1.62 | 26.565 | 3.473 | 2.143 | 3.526 | 4.965 | 23.053 | 12.162 | 3.476 | 2.235 | 1.465 | 0.63 | 0.265 | 0.074 | 0.516 |
| Cost of Revenue
| 4.632 | 8.326 | 8.177 | 5.824 | 2.687 | 18.502 | 0 | 0.815 | 14.381 | 0.078 | 9.573 | 7.005 | 7.039 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 41.386 | 33.078 | 28.762 | 28.613 | 17.678 | -15.541 | 7.539 | 0.805 | 12.184 | 3.395 | -7.43 | -3.479 | -2.074 | 23.053 | 12.162 | 3.476 | 2.235 | 1.465 | 0.63 | 0.265 | 0.074 | 0.516 |
| Gross Profit Ratio
| 0.899 | 0.799 | 0.779 | 0.831 | 0.868 | -5.249 | 1 | 0.497 | 0.459 | 0.978 | -3.467 | -0.987 | -0.418 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reseach & Development Expenses
| 64.662 | 49.642 | 28.5 | 17.424 | 15.368 | 16.178 | 14.88 | 14.381 | 12.088 | 9.573 | 7.005 | 7.039 | 6.864 | 6.994 | 8.007 | 14.426 | 20.03 | 11.702 | 6.294 | 4.872 | 3.081 | 1.795 |
| General & Administrative Expenses
| 40.102 | 34.817 | 25.575 | 20.726 | 17.939 | 11.545 | 11.235 | 9.013 | 8.056 | 7.468 | 7.169 | 6.868 | 8.104 | 6.968 | 8.791 | 13.951 | 13.951 | 0 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 11.689 | 25.507 | 27.503 | 25.293 | 29.772 | 1.512 | 1.512 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.969 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 51.791 | 60.324 | 53.078 | 46.019 | 47.711 | 13.057 | 11.235 | 9.013 | 8.056 | 7.468 | 7.169 | 6.868 | 8.104 | 6.968 | 8.791 | 13.951 | 12.982 | 15.884 | 3.808 | 1.602 | 0.566 | 0 |
| Other Expenses
| 0 | 2.05 | 2.46 | 2.46 | 2.46 | 14.835 | 8.311 | 13.983 | 0.003 | 7.262 | 6.225 | 19.789 | 3.252 | 3.252 | 0 | 71.204 | 4.765 | 1.555 | 0.782 | 0.027 | 0.025 | 0 |
| Operating Expenses
| 115.048 | 112.016 | 84.038 | 65.903 | 65.539 | 29.235 | 26.115 | 23.394 | 20.144 | 17.041 | 14.174 | 13.907 | 14.968 | 13.962 | 16.798 | 28.377 | 37.777 | 29.142 | 10.883 | 6.502 | 3.672 | 1.795 |
| Operating Income
| -75.067 | -78.938 | -55.276 | -37.29 | -47.861 | -26.274 | -18.576 | -21.774 | 6.421 | -13.49 | -12.031 | -25.211 | -10.003 | 9.091 | -4.636 | -24.901 | -35.542 | -27.676 | -10.254 | -6.237 | -3.598 | -1.795 |
| Operating Income Ratio
| -1.631 | -1.907 | -1.496 | -1.083 | -2.35 | -8.873 | -2.464 | -13.441 | 0.242 | -3.884 | -5.614 | -7.15 | -2.015 | 0.394 | -0.381 | -7.164 | -15.902 | -18.886 | -16.288 | -23.514 | -48.386 | -3.477 |
| Total Other Income Expenses Net
| 4.355 | -2.617 | -3.141 | -8.104 | -8.932 | -63.166 | -26.897 | 0.091 | 0.072 | 0.022 | 0.005 | 0.014 | 0.207 | 1.157 | -0.315 | 1.174 | 8.854 | -61.208 | -17.728 | 9.324 | -0.001 | -1.803 |
| Income Before Tax
| -70.712 | -102.254 | -58.417 | -45.394 | -56.793 | -53.171 | -18.485 | -21.702 | 6.443 | -13.485 | -12.017 | -25.004 | -8.846 | 8.776 | -3.462 | -76.153 | -127.203 | -27.982 | -11.486 | -5.225 | -3.598 | -2.252 |
| Income Before Tax Ratio
| -1.537 | -2.47 | -1.581 | -1.318 | -2.789 | -17.957 | -2.452 | -13.396 | 0.243 | -3.883 | -5.608 | -7.091 | -1.782 | 0.381 | -0.285 | -21.908 | -56.914 | -19.095 | -18.246 | -19.7 | -48.397 | -4.361 |
| Income Tax Expense
| 0.083 | 22.258 | 5.498 | 7.257 | 6.176 | -25.558 | -0.815 | -0.155 | 0.096 | -0.13 | -0.117 | -0.169 | -0.218 | 0.023 | -0.951 | -0.483 | -23.529 | -7.068 | -0.303 | -2.665 | -1.741 | -1.795 |
| Net Income
| -70.795 | -124.512 | -63.915 | -52.651 | -62.969 | -53.171 | -18.485 | -21.547 | 6.347 | -13.355 | -11.9 | -24.835 | -8.628 | 8.753 | -2.511 | -75.67 | -103.675 | -20.913 | -11.183 | -2.559 | -1.858 | -2.252 |
| Net Income Ratio
| -1.538 | -3.007 | -1.73 | -1.529 | -3.092 | -17.957 | -2.452 | -13.301 | 0.239 | -3.845 | -5.553 | -7.043 | -1.738 | 0.38 | -0.206 | -21.769 | -46.387 | -14.271 | -17.765 | -9.65 | -24.985 | -4.361 |
| EPS
| -1.82 | -3.34 | -2.22 | -4.1 | -6.04 | -11.5 | -5.23 | -6.81 | 2.16 | -4.87 | -5.16 | -11.95 | -4.43 | 4.76 | -1.37 | -41.65 | -93.93 | -27.81 | -21.53 | -0.84 | -7.32 | -5.48 |
| EPS Diluted
| -1.82 | -3.34 | -2.22 | -4.1 | -6.04 | -11.5 | -5.23 | -6.81 | 2.08 | -4.87 | -5.16 | -11.95 | -4.43 | 4.63 | -1.37 | -41.65 | -93.93 | -27.81 | -21.53 | -2.08 | -7.32 | -5.48 |
| EBITDA
| -69.001 | -96.619 | -50.148 | -35.488 | -48.013 | -36.994 | -18.576 | -17.67 | -20.866 | 7.303 | -12.651 | -11.037 | -22.777 | -5.491 | 9.091 | -0.024 | -75.646 | -22.046 | -18.977 | -9.437 | -5.996 | -3.385 |
| EBITDA Ratio
| -1.499 | -1.806 | -1.422 | -1.01 | -2.178 | -8.839 | -2.464 | -13.441 | 0.242 | -3.641 | -5.607 | 1.214 | -2.242 | 0.409 | -0.085 | 7.736 | 28.141 | -15.044 | -12.357 | -26.434 | -45.523 | -2.477 |